Comparison of 1st chemotherapy in unresectable locally advanced or metastatic PDAC
Arndt Vogel shared on X:
“Comparison of 1st chemotherapy in unresectable locally advanced or metastatic PDAC
systematic review and Bayesian network meta-analysis, 79 trials, 22 168 patients
NALIRIFOX and FOLFIRINOX may be the preferred options if feasible.”
Autors: Luca Mastrantoni, Marta Chiaravalli, Alexia Spring, Viria Beccia, Armando Di Bello, Cinzia Bagalà, Maria Bensi, Diletta Barone, Giovanni Trovato, Giulia Caira, Giulia Giordano, Prof Emilio Bria, Giampaolo Tortora,
Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer. He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023